Metastatic pancreatic cancer has, for a generation, been where good drugs go to disappoint. Second-line options buy weeks. So a hazard ratio of 0.40 for death — a median overall survival of 15.2 months against chemotherapy’s 6.6 in the RAS-mutant population of RASolute 302 — deserves to be read twice. This is not a surrogate endpoint or a press-release teaser. It is overall survival, the outcome that cannot be argued with.
It also matters why. RAS was called undruggable for forty years; its surface is smooth, its grip on GTP relentless. The KRAS-G12C inhibitors cracked one door. A pan-RAS approach that translates into survival in the most treatment-resistant solid tumor is the strongest signal yet that the entire pathway — not one mutation — is now therapeutic territory.
A hazard ratio of 0.40 in this disease is the kind of number you stop and read twice.
Now the discipline. “Roughly doubles survival” is true and still means most patients are measured in months, not years; this is a delay of death, not yet a cure. The result is in previously treated, RAS-mutant disease — the first-line and biomarker-defined questions are open, and confirmatory data will decide how durable the effect is. Tolerability, and whether a US list price lands anywhere near what a health system can absorb, will determine who actually benefits.
What changes today is the slope of the curve and the burden of proof: RAS-pathway inhibition has earned its place in the pancreatic-cancer conversation, and the next readouts will be watched the way oncology once watched the first checkpoint inhibitors. What does not change — yet — is what a clinician can promise a patient in the room. Cautious optimism is the correct prescription.